UNIVERSAL TECHNICAL INSTITUT (UTI) Stock Fundamental Analysis
USA - NYSE:UTI - US9139151040 - Common Stock
30.53 USD
-1.37 (-4.29%)
30.1108 USD
-0.42 (-1.37%)
We assign a fundamental rating of 6 out of 10 to UTI. UTI was compared to 75 industry peers in the Diversified Consumer Services industry. While UTI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. UTI is growing strongly while it is still valued neutral. This is a good combination! This makes UTI very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year UTI was profitable.
In the past year UTI had a positive cash flow from operations.
Each year in the past 5 years UTI has been profitable.
UTI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of UTI (8.52%) is better than 78.67% of its industry peers.
With an excellent Return On Equity value of 20.57%, UTI belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
UTI has a Return On Invested Capital of 10.86%. This is amongst the best in the industry. UTI outperforms 84.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for UTI is below the industry average of 9.63%.
The 3 year average ROIC (5.11%) for UTI is below the current ROIC(10.86%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.52% | ||
| ROE | 20.57% | ||
| ROIC | 10.86% |
ROA(3y)2.68%
ROA(5y)2.09%
ROE(3y)7.52%
ROE(5y)5.81%
ROIC(3y)5.11%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 7.79%, UTI is in the better half of the industry, outperforming 68.00% of the companies in the same industry.
UTI's Profit Margin has improved in the last couple of years.
The Operating Margin of UTI (10.44%) is better than 69.33% of its industry peers.
UTI's Operating Margin has improved in the last couple of years.
UTI has a Gross Margin (49.65%) which is comparable to the rest of the industry.
UTI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.44% | ||
| PM (TTM) | 7.79% | ||
| GM | 49.65% |
OM growth 3Y21.82%
OM growth 5YN/A
PM growth 3Y23.23%
PM growth 5YN/A
GM growth 3Y-14.8%
GM growth 5Y-8.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTI is still creating some value.
UTI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for UTI has been increased compared to 5 years ago.
The debt/assets ratio for UTI has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.03 indicates that UTI is not in any danger for bankruptcy at the moment.
The Altman-Z score of UTI (4.03) is better than 81.33% of its industry peers.
The Debt to FCF ratio of UTI is 0.99, which is an excellent value as it means it would take UTI, only 0.99 years of fcf income to pay off all of its debts.
UTI has a better Debt to FCF ratio (0.99) than 85.33% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that UTI is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.23, UTI is in line with its industry, outperforming 56.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 0.99 | ||
| Altman-Z | 4.03 |
ROIC/WACC1.29
WACC8.41%
2.3 Liquidity
A Current Ratio of 1.00 indicates that UTI should not have too much problems paying its short term obligations.
The Current ratio of UTI (1.00) is comparable to the rest of the industry.
A Quick Ratio of 1.00 indicates that UTI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.00, UTI is in line with its industry, outperforming 48.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 128.00% over the past year.
UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 28.35% yearly.
The Revenue has grown by 14.56% in the past year. This is quite good.
Measured over the past years, UTI shows a quite strong growth in Revenue. The Revenue has been growing by 17.19% on average per year.
EPS 1Y (TTM)128%
EPS 3Y28.35%
EPS 5YN/A
EPS Q2Q%111.11%
Revenue 1Y (TTM)14.56%
Revenue growth 3Y29.79%
Revenue growth 5Y17.19%
Sales Q2Q%15.12%
3.2 Future
The Earnings Per Share is expected to grow by 11.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.46% on average over the next years. This is quite good.
EPS Next Y44.87%
EPS Next 2Y15.65%
EPS Next 3Y11.29%
EPS Next 5YN/A
Revenue Next Year14.42%
Revenue Next 2Y11.32%
Revenue Next 3Y10.46%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 26.78, the valuation of UTI can be described as expensive.
UTI's Price/Earnings is on the same level as the industry average.
UTI is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.31, which is the current average of the S&P500 Index.
UTI is valuated quite expensively with a Price/Forward Earnings ratio of 30.84.
UTI's Price/Forward Earnings ratio is in line with the industry average.
UTI's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.85.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.78 | ||
| Fwd PE | 30.84 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, UTI is valued a bit cheaper than the industry average as 61.33% of the companies are valued more expensively.
UTI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. UTI is cheaper than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.23 | ||
| EV/EBITDA | 13.47 |
4.3 Compensation for Growth
UTI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UTI has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.6
PEG (5Y)N/A
EPS Next 2Y15.65%
EPS Next 3Y11.29%
5. Dividend
5.1 Amount
No dividends for UTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
30.53
-1.37 (-4.29%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)
Earnings (Next)
Inst Owners94.48%
Inst Owner Change0.03%
Ins Owners2.24%
Ins Owner Change-1.76%
Market Cap1.66B
Analysts81.82
Price Target38.18 (25.06%)
Short Float %3.66%
Short Ratio2.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.27%
Min EPS beat(2)69.26%
Max EPS beat(2)73.27%
EPS beat(4)4
Avg EPS beat(4)69.47%
Min EPS beat(4)12.21%
Max EPS beat(4)123.12%
EPS beat(8)7
Avg EPS beat(8)80.23%
EPS beat(12)10
Avg EPS beat(12)129.78%
EPS beat(16)14
Avg EPS beat(16)215.22%
Revenue beat(2)2
Avg Revenue beat(2)2.83%
Min Revenue beat(2)1.15%
Max Revenue beat(2)4.51%
Revenue beat(4)4
Avg Revenue beat(4)2.54%
Min Revenue beat(4)1.15%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.39%
Revenue beat(12)11
Avg Revenue beat(12)2.98%
Revenue beat(16)15
Avg Revenue beat(16)3.43%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.84%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)1.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.78 | ||
| Fwd PE | 30.84 | ||
| P/S | 2.05 | ||
| P/FCF | 22.23 | ||
| P/OCF | 15.42 | ||
| P/B | 5.42 | ||
| P/tB | 6.37 | ||
| EV/EBITDA | 13.47 |
EPS(TTM)1.14
EY3.73%
EPS(NY)0.99
Fwd EY3.24%
FCF(TTM)1.37
FCFY4.5%
OCF(TTM)1.98
OCFY6.49%
SpS14.88
BVpS5.64
TBVpS4.79
PEG (NY)0.6
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.52% | ||
| ROE | 20.57% | ||
| ROCE | 15.21% | ||
| ROIC | 10.86% | ||
| ROICexc | 13.78% | ||
| ROICexgc | 15.4% | ||
| OM | 10.44% | ||
| PM (TTM) | 7.79% | ||
| GM | 49.65% | ||
| FCFM | 9.23% |
ROA(3y)2.68%
ROA(5y)2.09%
ROE(3y)7.52%
ROE(5y)5.81%
ROIC(3y)5.11%
ROIC(5y)N/A
ROICexc(3y)7.05%
ROICexc(5y)N/A
ROICexgc(3y)7.97%
ROICexgc(5y)N/A
ROCE(3y)7.15%
ROCE(5y)N/A
ROICexcg growth 3Y41.64%
ROICexcg growth 5YN/A
ROICexc growth 3Y37.09%
ROICexc growth 5YN/A
OM growth 3Y21.82%
OM growth 5YN/A
PM growth 3Y23.23%
PM growth 5YN/A
GM growth 3Y-14.8%
GM growth 5Y-8.67%
F-Score6
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 0.99 | ||
| Debt/EBITDA | 0.58 | ||
| Cap/Depr | 87.82% | ||
| Cap/Sales | 4.08% | ||
| Interest Coverage | 11.6 | ||
| Cash Conversion | 88.25% | ||
| Profit Quality | 118.43% | ||
| Current Ratio | 1 | ||
| Quick Ratio | 1 | ||
| Altman-Z | 4.03 |
F-Score6
WACC8.41%
ROIC/WACC1.29
Cap/Depr(3y)259.47%
Cap/Depr(5y)259.17%
Cap/Sales(3y)10.54%
Cap/Sales(5y)10.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128%
EPS 3Y28.35%
EPS 5YN/A
EPS Q2Q%111.11%
EPS Next Y44.87%
EPS Next 2Y15.65%
EPS Next 3Y11.29%
EPS Next 5YN/A
Revenue 1Y (TTM)14.56%
Revenue growth 3Y29.79%
Revenue growth 5Y17.19%
Sales Q2Q%15.12%
Revenue Next Year14.42%
Revenue Next 2Y11.32%
Revenue Next 3Y10.46%
Revenue Next 5YN/A
EBIT growth 1Y85.69%
EBIT growth 3Y58.11%
EBIT growth 5YN/A
EBIT Next Year114.2%
EBIT Next 3Y30.39%
EBIT Next 5YN/A
FCF growth 1Y395.38%
FCF growth 3YN/A
FCF growth 5Y32.12%
OCF growth 1Y222.73%
OCF growth 3Y15.89%
OCF growth 5Y31.61%